Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of Brivekimig in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT06975722 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06975722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of Brivekimig in Adult Participants With Moderate to Severe Ulcerative Colitis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 7, 2025
Completion date
October 17, 2029
Enrollment
105 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis